346669-50-9

Usage

Uses

Used in Pharmaceutical Industry:
Baclofen is utilized as a muscle relaxant for the treatment of muscle spasms, cramping, and tightness. It is particularly beneficial for conditions such as multiple sclerosis, spinal cord injuries, and cerebral palsy. The medication can be administered orally or intrathecally to provide relief from the symptoms associated with these conditions.
Additionally, baclofen has been investigated for its potential applications in treating alcoholism, opioid withdrawal, and other neurological disorders due to its effects on the central nervous system.
However, it is important to note that baclofen can have side effects, including drowsiness, dizziness, and muscle weakness. Therefore, its use should be closely monitored by a healthcare professional to ensure safe and effective treatment.

Upstream product

• 190393-64-7 (S)-2-[(benzyloxycarbonyl)amino]propan-1-yl azide 
• 17343-54-3 (S)-2-(benzyloxycarbonylamino)-propionitrile 
• 13139-27-0 L-α-N-Cbz-alaninamide 
• 2251-65-2 3-(Trifluoromethyl)benzoyl chloride 
• 400652-52-0 (R)-2-(benzyloxycarbonylaminopropyl)carbamic acid tert-butyl ester 
• 78-90-0 (R)-1,2-diaminopropane 
• 28170-07-2 benzyl phenyl carbonate 
• 15967-72-3 (S)-1,2-diaminopropane 
• 6429-44-3 (S)-(-)-N-(benzyloxycarbonyl)alaninol 

Downstream Products

• 400652-51-9 C₁₆H₂₄N₂O₄ 

Relevant academic research and scientific papers

PANTOTHENAMIDE ANALOGUES

The present invention provides compounds that have antimalarial activity. More in particular, the present invention provides novel compounds that are analogues of pantothenamides. The pantothenamide analogues of this invention have particularly low ICsub

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

β-PNA: Peptide nucleic acid (PNA) with a chiral center at the β-position of the PNA backbone

Peptide nucleic acid (PNA) monomers with a methyl group at the β-position have been synthesized. The modified monomers were incorporated into PNA oligomers using Fmoc chemistry for solid-phase synthesis. Thermal denaturation and circular dichroism (CD) studies have shown that PNA containing the S-form monomers was well suited to form a hybrid duplex with DNA, whose stability was comparable to that of unmodified PNA-DNA duplex, whereas PNA containing the R-form monomers was not.

Parallel synthesis of an oligomeric imidazole-4, 5-dicarboxamide library

A library of oligomeric compounds was synthesized based on the imidazole-4, 5-dicarboxylic acid scaffold along with amino acid esters and chiral diamines derived from amino acids. The final compounds incorporate nonpolar amino acids (Leu, Phe, Trp), polar amino acids (Ser, Asp, Arg), and neutral amino acids (Gly, Ala), and were designed to be useful in screening for inhibitors of protein-protein interactions. Many of the protected and deprotected oligomers show evidence of conformational isomers persistent at room temperature in aqueous solution. A total of 317 final oligomers, out of 441 targeted compounds, were obtained in high analytical purity and of sufficient quantity to submit them for high-throughput screening as part of the NIH Roadmap.

AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.

N-urethane-protected amino alkyl isothiocyanates: Synthesis, isolation, characterization, and application to the synthesis of thioureidopeptides

(Chemical Equation Presented) Synthetically useful N-Fmoc amino-alkyl isothiocyanates have been described, starting from protected amino acids. These compounds have been synthesized in excellent yields by thiocarbonylation of the monoprotected 1,2-diamines with CS2/TEA/p-TsCl, isolated as stable solids, and completely characterized. The procedure has been extended to the synthesis of amino alkyl isothiocyanates from Boc- and Z-protected amino acids as well. The utility of these isothiocyanates for peptidomimetics synthesis has been demonstrated by employing them in the preparation of a series of dithioureidopeptide esters. Boc-Gly-OH and Boc-Phe-OH derived isothiocyanates 9a and 9c have been obtained as single crystals and their structures solved through X-ray diffraction. They belong to the orthorhombic crystal system, and have a single molecule in the asymmetric unit (Z′ = 1). 9a crystallizes in the centrosymmetric space group Pbca, while 9c crystallizes in the noncentrosymmetric space group P212121.

A simple approach for the synthesis of new classes of dithiocarbamate-linked peptidomimetics

An efficient protocol for the synthesis of a new series of dithiocarbamate-linked peptidomimetics is described. The in situ generated dithiocarbamic acid intermediate formed by the reaction of an amino acid ester and carbon disulfide in the presence of triethylamine was treated with N-protected amino alkyl iodide to afford title compounds 3a-g in good to moderate yields. The synthesis of N-Fmoc-protected tripeptidomimetics 4a-e containing two dithiocarbamate linkages is also described. The protocol was further extended to synthesize N,N′-orthogonally protected dithiocarbamate-linked dipeptidomimetics 7a-c as well. The mild reaction conditions and non-toxic reagents are the advantages of the present method.

New pyrrole-based amino acids for the synthesis of peptidomimetic constrained scaffolds

A new family of pyrrole-based amino acids have been prepared through the microwave assisted Paal-Knorr reaction of 1-4 ketoesters derived from the corresponding β-ketoester with a functional homologation. The carboxylic group is located in position 3 of the pyrrole, whereas the amino group, protected with the Cbz moiety, is present on the side chain in positions 1 or 2. These compounds were used to prepare constrained oligopeptides.

Diacyl derivatives of propylene diamine having herbicidal activity

Novel herbicidal compounds are provided having the formula (I) wherein one of R1a and R1b is a methyl, hydroxymethyl or monohalomethyl group and the other is hydrogen; R2 is a group R3—(X1)m/sub